Fragile X Syndrome (FXS) Market

The total cases of Fragile X Syndrome (FXS) in the 7MM was 117,962 in 2017. While in the United States, the diagnosed prevalent cases of FXS in 2017 was found to be 67,654.

The market size of Fragile X Syndrome (FXS) was USD 33.8 Million in 2017 and is expected to increase during the forecast period 2017-2030.

The key pharma companies in the Fragile X Syndrome (FXS) market include Zynerba Pharmaceuticals, Tetra Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, Marinus Pharmaceuticals, Alcobra Pharmaceuticals/ Arcturus Therapeutics and many others.

For more detailed information on Fragile X Syndrome (FXS) market, visit: https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market